The specter of generic challenges has consistently loomed over copyright’s blockbuster drug, Viagra, triggering questions about the prospects of related medicinal ventures. While early periods saw significant gains, the intellectual property expiration has created the way for less expensive substitutes, possibly diminishing revenue and posing a g